Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aspyrian Therapeutics Inc.
DescriptionCetuximab conjugated to IRDye 700DX, a chemical dye activated upon near-infrared light illumniation, to induce cell death in cells expressing epidermal growth factor receptor (EGFR)
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationHead and neck cancer
Indication DetailsTreat recurrent head and neck cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today